FDA clears first blood test to diagnose Alzheimer’s disease

A groundbreaking blood test for Alzheimer’s disease has been approved by U.S. regulators, offering a promising tool for early detection and treatment of the condition—affecting nearly 7 million Americans. Made by Fujirebio Diagnostics, this test detects amyloid protein in the blood, which is linked to the disease's progression. It is cleared for individuals over 55 who exhibit signs or symptoms of Alzheimer’s, marking a significant step toward making treatments more accessible. Notably, the test can identify cases where amyloid begins to accumulate long before symptoms appear, potentially enabling earlier intervention and personalized care.